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Abstract Human muscle undergoes constant changes.
After about age 50, muscle mass decreases at an annual
rate of 1–2%. Muscle strength declines by 1.5% between
ages 50 and 60 and by 3% thereafter. The reasons for these
changes include denervation of motor units and a net
conversion of fast type II muscle fibers into slow type I
fibers with resulting loss in muscle power necessary for
activities of daily living. In addition, lipids are deposited in
the muscle, but these changes do not usually lead to a loss
in body weight. Once muscle mass in elderly subjects falls
below 2 standard deviations of the mean of a young control
cohort and the gait speed falls below 0.8 m/s, a clinical
diagnosis of sarcopenia can be reached. Assessment of
muscle strength using tests such as the short physical
performance battery test, the timed get-up-and-go test, or
the stair climb power test may also be helpful in establish-
ing the diagnosis. Sarcopenia is one of the four main
reasons for loss of muscle mass. On average, it is estimated
that 5–13% of elderly people aged 60–70 years are affected
by sarcopenia. The numbers increase to 11–50% for those
aged 80 or above. Sarcopenia may lead to frailty, but not all
patients with sarcopenia are frail—sarcopenia is about
twice as common as frailty. Several studies have shown
that the risk of falls is significantly elevated in subjects with
reduced muscle strength. Treatment of sarcopenia remains
challenging, but promising results have been obtained using
progressive resistance training, testosterone, estrogens,
growth hormone, vitamin D, and angiotensin-converting
enzyme inhibitors. Interesting nutritional interventions
include high-caloric nutritional supplements and essential
amino acids that support muscle fiber synthesis.
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1 A history of muscle loss
Muscle is key to motion. As we age, significant changes in
muscle mass and quality take place. After about age 50,
muscle mass decreases at an annual rate of 1–2% [1, 2].
The decline in muscle strength is even higher, amounting to
1.5% per year between ages 50 and 60 and 3% per year
thereafter. These findings have only received systematic
research over the last two or three decades during which
interest in age-related changes in physiologic function
increased. This fact appears indeed curious because
Macdonald Critchley, then junior neurologist at King’s
College Hospital in London, wrote already in 1931 that
“the entire musculature tends with advancing age to
undergo involutional changes, which are manifested as
wasting” [3]. He went on saying that “probably the chief
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process of senile atrophy, which shows itself in the muscles
and elsewhere.” Later on, in the 1970s, Nathan Shock
published a series of articles on age-related physiologic
functions using data from the first large-scale longitudinal
study in this field [4]. Altogether, it evolved that no decline
in structure and function is more dramatic than the decline
in muscle mass that develops as we age. Irwin Rosenberg
realized that if this phenomenon were to be taken seriously,
a name was required, and at a meeting in Albuquerque,
New Mexico, in 1988, he suggested to use the term
sarcopenia [5]. Following the recommendation by Morley,
the term took hold over these last 20 years [6].
2 How to measure muscle mass and muscle strength?
The name sarcopenia is derived from Greek sarx (flesh) and
penia (loss), literally meaning poverty of flesh. Sarcopenia
is one of the four main reasons for loss of muscle mass, the
others being anorexia, dehydration, and cachexia [7, 8]. It is
difficult to estimate the prevalence of sarcopenia (Table 1),
mostly because of practical difficulties in assessing muscle
mass. Many different methodologies have been used over
the last 20 years, and new techniques are still being
introduced. On average, it is estimated that 5–13% of
elderly people aged 60–70 years are affected by sarcopenia,
and the numbers increase to 11–50% for those aged 80 or
above. Sarcopenia may lead to frailty, but not all patients
with sarcopenia are frail. In essence, sarcopenia is about
twice as common as frailty [9].
The broadness in the range of sarcopenia prevalence is
partly due to the heterogenecity of study populations, but
also due to the different techniques used to assess muscle
mass. Dual-energy X-ray absorptiometry (DEXA) is cur-
rently considered the gold standard. The name is derived
from the fact that two X-ray beams are used with different
energy levels of minimal intensity [10]. Other methods used
to measure muscle mass include bioelectrical impedance,
computed tomography, magnetic resonance imaging, urinary
excretion of creatinine, anthropometric assessments, and
neutron activation assessments [7]. Depending on the actual
technique used in different studies and on the cutoff values
chosen, the prevalenceofmusclemassmay varyconsiderably
(Table 1). Many institutions use handgrip strength as a
standard measure for assessing muscle strength. Physical
performance can be analyzed using simple and easy-to-do
tests such as the short physical performance battery test [11],
usual gait speed [12], the timed get-up-and-go test [13], or
the stair climb power test [14].
3 Pathophysiological changes in sarcopenia
Using such techniques, it became clear that aging is
associated with changes not only in muscle mass but also
Table 1 Large-scale studies into the prevalence of sarcopenia
Cohort
(country)
n (% female) Age Sarcopenia definition
(assessment method)
Sarcopenia
prevalence
Reference
CHS (USA) 5036 (56.4%) >65 years Categories of skeletal mass index,
defined as muscle mass normalized
for height (BIA)
Moderate sarcopenia, m: 70.7%,
f: 41.9%; severe sarcopenia, m:
17.1%, f: 10.7%
[35]
EPIDOS
(France)
1458 (100%) All >70 years;
mean 80.3±
3.8 years
Appendicular skeletal muscle mass
<2 SD below the mean of a young
female reference group (DEXA)
9.5% [36]
InCHIANTI
(Italy)
1030 (54.5) Range 20–102 Calf muscle cross sectional area
more than 2 SD below population
mean (CT scan)
m: 20% at 65 years, 70% at 85 years
f: 5% at 65 years, 15% at 85 years
[37]
NHANES
III (USA)
14818 >18 years; 30%
>60 years
Skeletal mass index was defined as
muscle mass/body mass x 100;
sarcopenia class I defined as
skeletal muscle mass 1–2 SD,
sarcopenia class II defined as
skeletal muscle mass >2 SD from
the mean of young subjects (BIA)
In subjects aged >60 years:
sarcopenia class I, m: 45%, f:
59%; sarcopenia class II:
m: 7%, f: 10%
[21]
NMEHS
(USA)
808 (47.3%) m: 73.6±
5.8 years; f:
73.7±6.1 years
Appendicular skeletal muscle mass
<2 SD below the mean of a young
reference population (substudy
of DEXA)
<70 years, m: 13.5–16.9%, f: 23.1–24.1%;
70–74 years, m: 18.3–19.8%, f: 33.3–
35.1%; 75–80 years, m: 26.7–36.4%, f:
35.3–35.9%; >80 years, m: 52.6–57.6%,
f: 43.2–60.0%
[19]
BIA bioelectrical impedance assessment, CHS Cardiovascular Health Study, CT computed tomography, DEXA dual-energy X-ray absorptiometry,
EPIDOS European Patient Information and Documentation Systems, NHANES National Health and Nutrition Examination Survey, NMEHS New
Mexico Elder Health Study, SD standard deviation
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ties of muscle as well as in the function of tendons [15].
In aging muscle, there is a loss of motor units via
denervation. These denervated motor units are recruited
by surviving motor units, which puts an increased burden of
work on them.
Altogether, there is a net conversion of fast type II
muscle fibers into slow type I fibers with resulting loss in
muscle power necessary for activities of daily living such as
rising from a chair or climbing steps [15]. Other aspects
include the deposition of lipids within muscle fibers. These
effects—in contrast to cachexia [8]—do not lead to a net
loss in body weight, but to a significant reduction in muscle
strength. Indeed, in healthy volunteers, the maximal
velocity during cycle ergometry decreased by 18%
from the third age decade (20–29 years) to the sixth
(50–59 years) [16]. Another 20% were lost between the
seventh (60–69 years) and the ninth age decade (80–
89 years) [16]. The loss of maximal oxygen consumption
(peak VO2) with increasing age has also been attributed
to reduced muscle mass and cardiac output [15]. The risk
of falls and consequently of fractures is closely related to
reduced muscle mass as well: After multivariable adjust-
ment, a 2.3-fold increase in the risk of falls was reported
for patients in the lower third of handgrip strength as
compared to the upper third [17]. Likewise, another
large-scale study in more than 2,100 elderly subjects
found that a low walking speed is an independent risk
factor of falls [18].
4 Making a diagnosis of sarcopenia
Using the above knowledge, it does not come as a surprise
that the likelihood of having a physical disability is higher
in elderly subjects who present with height-adjusted
appendicular muscle mass 2 standard deviations below the
mean of young adult as compared to those with normal
muscle mass [19]. Having said that, the difficulty in making
a correct diagnosis of sarcopenia is easily understood.
Several definitions and diagnostic criteria have been
proposed over the last 20 years. Many of them are not
easily applicable in daily clinical practice.
A consensus definition formulated by experts from a
vast array of different medical fields recently suggested to
diagnose sarcopenia when two criteria are fulfilled: (1) a
low muscle mass and (2) a low gait speed [20]. Normal
muscle mass is defined using data derived from young
subjects aged 18–39 years from the Third NHANES
population [21], and the requirement for a diagnosis of
sarcopenia is the presence of a muscle mass ≥2 standard
deviations below the mean of this reference population.
This value can normally be calculated automatically by
equipment such as DEXA-scanners. A low gait speed is
defined as a walking speed below 0.8 m/s in the 4-m
walking test [22]. The European Working Group on
Sarcopenia in Older People suggested diagnosing sarcopenia
when at least two of three criteria apply: (1) low muscle mass,
(2) low muscle strength, and/or (3) low physical performance
[23]. Cutoff points are defined in a similar manner as by the
consensus group mentioned before, namely 2 standard
deviations below the mean reference value for muscle mass
and muscle strength of a reference population and a gait
speed ≤0.8 m/s.
5 Treatment approaches to sarcopenia
A diagnosis of sarcopenia remains a rare case. But even if
the diagnosis is reached, the treatment of sarcopenia
remains challenging. Many different approaches have been
pursued, but exercise and physical activity are important
considerations for both sarcopenia prophylaxis [24, 25] and
sarcopenia management [26]. Progressive resistance train-
ing, performed 2–3 times per week by older people, has
been shown to improve gait speed, timed get-up-and-go,
climbing stairs, and overall muscle strength [27]. Nutri-
tional interventions also have an important impact. Current
recommendations state that protein should be consumed at
a rate of 0.8 g/kg/day, but about 40% of persons above the
age of 70 years do meet this amount [28]. Additional
calorie intake of 360 cal per day together with resistance
exercise training has been shown to increase leg muscle
strength in nursing home residents after 10 weeks. Similar
effects were described in cachectic patients [29]. Supple-
mentation of essential amino acids has been shown to
improve handgrip strength and 6-min walking distance in
elderly subjects after 3 months [30]. Other therapeutic
approaches include the use of testosterone, estrogens,
growth hormones, vitamin D, and angiotensin-converting
enzyme inhibitors [7, 25, 31]. In addition, animal studies
have recently reported beneficial effects of soluble activin
receptor type IIB (ActRIIB) treatment [32] and myostatin
inhibition [33].
The first step in the sarcopenia journey is to create more
awareness of this clinical problem, both by the general
public and by healthcare professionals. In this respect, the
implementation of standardized diagnostic criteria was
extremely important. However, sarcopenia is a phenom-
enon that is present not only in healthy elderly subjects
but also in those with chronic illnesses, such as chronic
heart or renal failure. A debate exists as to whether
muscle loss should be termed sarcopenia under these
conditions as well. More prospective studies are required
to understand the prevalence, incidence, phenotype, and
the clinical impact of sarcopenia. Such studies are only
J Cachexia Sarcopenia Muscle (2010) 1:129–133 131beginning to emerge. Furthermore, the discussion con-
tinues whether sarcopenia, i.e., loss of muscle mass,
should be separated from dynopenia, i.e., loss of power.
Also, as enthusiasts try to make sarcopenia all encom-
passing by adding a functional definition, the definition
lines between frailty and sarcopenia are becoming
blurred. There is a need for a consensus decision
regarding the use of these terms.
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